
|Videos|September 19, 2022
Dr. Shore on next steps with PARP inhibitors in prostate cancer
Author(s)Urology Times staff
Advertisement
Neal D. Shore, MD, discusses what’s on the horizon with PARP inhibitors in the treatment paradigm for patients with prostate cancer. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5










